Tafamidis 是选择性的transthyretin (TTR)稳定剂，对野生型 WT-TTR 、突变型同源四聚体 V30M-TTR、V122I-TTR 的活性相当，它们的EC50值为2.7-3.2 μM。它对淀粉样蛋白的生成具有抑制作用。

Tafamidis is a kinetic stabilizer of transthyretin (TTR) that prevents amyloidogenesis by wild-type and mutant TTRs. It binds to TTR with negative cooperativity (Kd1: 3 nM; Kd2: 278 nM) to stabilize the TTR dimer-dimer interface and inhibit tetrameric dissociation. Tafamidis stabilizes wild-type and clinically significant V30M and V122I mutant TTR amyloidogenic homotetramers (EC50s: 2.7-3.2 μM) under fibril-promoting, denaturing, and physiological conditions in vitro. It stabilizes TTR heterotetramers containing wild-type and mutant subunits ex vivo in human plasma derived from patients carrying V30M or V1221 mutations when used at a concentration of 7.2 μM. Formulations containing tafamidis have been used for the treatment of familial amyloid polyneuropathy.

594839-88-0

C14H7Cl2NO3

308.11

他发米帝司甲葡胺;氯苯唑酸;Fx-1006A;Tafamidis

DMSO:10 mg/mL
Ethanol:2 mg/mL
Powder: -20°C for 3 years
In solvent: -80°C for 2 years